Welcome to the exciting collaboration between Hydreight and Semaglutide, where innovative marketing strategies meet groundbreaking pharmaceutical developments. Come join us in reshaping the way we approach metabolic management and weight loss support.

Together, let's pave the way for a healthier future.

Are you eager to learn more about capitalizing on this groundbreaking opportunity to generate income?

Hydreight: How to Market Your Mobile Services

Introducing Semaglutide

One notable addition to our platform is the introduction of Semaglutide, a groundbreaking release poised to revolutionize the industry. This presents an exciting opportunity for businesses to incorporate this innovative product into their offerings and sometimes businesses need a little extra push to reach their full potential.

Whether it's fine-tuning your sales strategy or providing personalized support, we're dedicated to helping you unlock new opportunities and achieve your goals.

Buzz
Marketing Content (1)

How are clients doing it?

Check out our Success Spotlight to learn more about how existing Hydreight nurses are marketing their weight management program:

Screenshot 2024-03-21 141055
Click the image above to see the Success Spotlight!

Educational Content

 

Marketing Partnerships
Referral Program Designed exclusively for your valued customers An easy way to earn rewards while sharing the success of your program with friends and family Rewards could include discounts on you-1
  •  

timeline

 

Your Health (1)

Semaglutide Disclaimer

By offering compounded drug products containing semaglutide you acknowledge and agree with the following statements:
1.       These products are compounded drug products containing semaglutide. They are not Ozempic, Wegovy, or Rybelsus, which are FDA approved and commercially available drug products manufactured by Novo Nordisk.
2.       You will not market or advertise the products as Ozempic, Wegovy, or Rybelsus or suggest any association with those products or with Novo Nordisk.
3.       You will not market or advertise the products as being approved by FDA, reviewed by FDA for safety, effectiveness, or quality, or demonstrated to FDA to be safe and effective for their intended use.
4.       You will not make any claims or suggest in any way that the products are proven to achieve certain therapeutic results or effects.
5.       These products may only be administered to the individual patient for which they were compounded following a good faith examination and pursuant to a practitioner’s order.
6.       You understand that compounded drug products such as Semglutide are not FDA approved but are able to be compounded in certain circumstances. Compounding of these products is permitted because Ozempic and Wegovy are currently listed on the FDA Drug Shortages List. If that regulatory status changes, then the availability of compounded drug products containing Semaglutide may change.


For additional information, see the below resources:
a.       FDA Press Release, Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss (October 31, 2023)
b.       Novo Nordisk Company Statement, Novo Nordisk takes additional legal actions to help protect US patients from potentially unsafe and ineffective compounded drugs claiming to contain semaglutide that are not FDA approved (November 29, 2023)